Phase II Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer
Summary
3/16/2020 NOTE: This trial has now completed the first part of Arm A (no GVAX will be given).
The purpose of this phase II study is to determine the recommended dose of epacadostat in different combinations, as well as assess the survival of patients in both treatment groups.
General Information
NCT#: NCT03006302
Study ID: J16173
Trial Phase: Phase II
Trial Sponsor: Johns Hopkins University
Therapies Used in This Trial: GVAX, Cyclophosphamide, CRS-207, Pembrolizumab, Epacadostat